The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Filippo Pietrantonio, Lorenza Rimassa et al.|British Journal of Cancer|2020Cited by 350
RET fusions in solid tumorsAndrew Y. Li, Christian Rolfo, Michael G. McCusker et al.|Cancer Treatment Reviews|2019Cited by 251
Breast Safety and Efficacy of Genistein Aglycone for Postmenopausal Bone Loss: A Follow-Up StudyHerbert Marini, Francesco Squadrito, Alessandra Bitto et al.|The Journal of Clinical Endocrinology & Metabolism|2008Cited by 168
Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)Michelino De Laurentiis, Grazia Arpino, Luca Malorni et al.|Cancer Research|2020Cited by 6